EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study

Achille Marino, Maria Vittoria Cicinelli, Elisabetta Miserocchi, Stefania Costi, Francesco Baldo, Maurizio Virgilio Gattinara, Pierluigi Scandale, Scott D Smith, Debra A Goldstein, Dina Baddar, Terese K A Gerges, Timothy M Janetos und 20 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43165 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Achille Marino und 31 weiteren Autor:innen. Beteiligte Einrichtung: ASST Gaetano Pini-CTO, Milan, Italy. Hauptthemen laut MEDLINE: Adalimumab, Uveitis, Antirheumatic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk.

Methods

We conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis. Cox proportional hazards regression was used to analyze risk factors for NIU recurrence.

Results

The study cohort comprised 114 patients (65 girls; 57%). Most commonly, patients presented with juvenile idiopathic arthritis–associated uveitis (JIA‐U) (52 of 114; 46%) or idiopathic uveitis (46 of 114; 40%). At ADA tapering, 46% of patients (53 of 114) experienced NIU recurrence after an overall median time of 30 weeks (interquartile range [IQR] 15–58 weeks) from the start of ADA tapering. Patients without recurrences were observed for a median of 70 weeks (IQR 48–98 weeks). Multivariate Cox regression analysis showed that a slower ADA tapering schedule was associated with a lower recurrence rate during the waning (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.21–0.74; P < 0.01). Subgroup analysis of patients with JIA‐U indicated that beginning ADA tapering after at least two years of disease inactivity significantly reduced recurrence risk (HR 0.65, 95% CI 0.43–0.95; P = 0.05). Among 59 patients (52%) who discontinued ADA, recurrence rates were similar between fast‐ and slow‐tapering groups (21% vs 33%; P = 0.6), but median time to recurrence was shorter with fast tapering (10 weeks vs 37 weeks; P = 0.05).

Conclusion

This study highlights the significant clinical impact of ADA tapering on uveitis recurrence risk, recommending a gradual, slow‐tapering approach with close monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabUveitisAntirheumatic AgentsHumansFemaleRetrospective StudiesMaleChildRecurrenceAdolescentArthritis, JuvenileRisk FactorsProportional Hazards ModelsChild, Preschool

Substanzen

AdalimumabAntirheumatic Agents

Autor:innen und Institutionen

  • ASST Gaetano Pini-CTO, Milan, Italy.
  • Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, and Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio.
  • Northwestern University, Chicago, Illinois.
  • Watany Eye Hospital, Cairo, Egypt, and Research Institute of Ophthalmology, Giza, Egypt.
  • Watany Eye Hospital, Cairo, Egypt.

ORCID-Profile: Cecilia B Chighizola

Zitieren

APA

Marino, A., Cicinelli, M. V., Miserocchi, E., Costi, S., Baldo, F., Gattinara, M. V., Scandale, P., Smith, S. D., Goldstein, D. A., Baddar, D., Gerges, T. K. A., Janetos, T. M., Ruiz-Cruz, M., Maruyama, K., Serafino, M., Camicione, P., Gupta, V., Amer, R., Dodds, E. M., …, & Pichi, F. (2025). Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.43165

Vancouver

Marino A, Cicinelli MV, Miserocchi E, Costi S, Baldo F, Gattinara MV, et al. Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study. Arthritis & Rheumatology. 2025. doi:10.1002/art.43165

BibTeX
@article{Marino2025,
  author = {Marino, Achille and Cicinelli, Maria Vittoria and Miserocchi, Elisabetta and Costi, Stefania and Baldo, Francesco and Gattinara, Maurizio Virgilio and Scandale, Pierluigi and Smith, Scott D and Goldstein, Debra A and Baddar, Dina and Gerges, Terese K A and Janetos, Timothy M and Ruiz-Cruz, Matilde and Maruyama, Kazuichi and Serafino, Massimiliano and Camicione, Paola and Gupta, Vishali and Amer, Radgonde and Dodds, Emilio M and Inchauspe, Sebastian and Munk, Marion R and Carreño, Ester and Chee, Soon-Phaik and Agarwal, Aniruddha and Schlaen, Ariel and Gómez, Ramiro A and Couto, Cristobal A and Khairallah, Moncef and Neri, Piergiorgio and Chighizola, Cecilia B and Caporali, Roberto F and Pichi, Francesco},
  title = {Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43165}
}
Kostenlos starten →